2.33MMarket Cap-226P/E (TTM)
2.4500High2.1678Low51.03KVolume2.4500Open2.2300Pre Close116.14KTurnover4.85%Turnover RatioLossP/E (Static)1.06MShares18.810052wk High0.47P/B2.32MFloat Cap2.167852wk Low--Dividend TTM1.05MShs Float3118.4994Historical High--Div YieldTTM12.66%Amplitude2.1670Historical Low2.2750Avg Price1Lot Size
Phio Pharmaceuticals Stock Forum
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Phio Pharmaceuticals (NASDAQ: PHIO) announced new clinical data presentation from its ongoing Phase 1b trial at the 39th Annual SITC Meeting. The trial evaluates PH-762 through intratumoral injection in patients with various skin cancers. Results show the treatment has been well-tolerated with no adverse events across five patient...
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is presenting data on its INTASYL compound PH-894 at the ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer conference. The presentation focuses on how PH-894 improves the functionality and cytotoxicity of Natural Killer (NK) cells in fighting cancer:
1. PH-894 leads to pote...
No comment yet